shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)

    RFA-DA-25-021

    National Institutes of Health

    Opening date 30 Oct 2023, 12:00AM

    Closing date 15 Nov 2024, 12:00AM

    Funding Opportunity Number: RFA-DA-25-021

    Opportunity Category: Discretionary

    CFDA Number(s): 93.279 -- Drug Abuse and Addiction Research Programs

    Cost Sharing or Matching Requirement: No

    Posted Date: Oct 30, 2023 12:00:00 AM EDT

    Closing Date: Nov 15, 2024 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Native American tribal governments (Federally recognized),County governments,Special district governments,City or township governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Independent school districts,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,Private institutions of higher education,State governments,Public and State controlled institutions of higher education,Public housing authorities/Indian housing authorities,Others (see text field entitled "Additional Information on Eligibility" for clarification),For profit organizations other than small businesses

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV. However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death. Optimal development and functioning of the placenta are key factors in maintenance of pregnancy and positively corelate with maternal and fetal outcomes. Despite this, there is considerable paucity of data on the impact of HIV/ART exposure on the placenta. Even less is known on the impact of HIV/ART exposure on the placenta in pregnant individuals with substance use/misuse.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept